• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMC Genomics . Phylogenetic analysis and comparative genomics of SARS-CoV-2 from survivor and non-survivor COVID-19 patients in Cordoba, Argentina

tetano

Editor, Senior Moderator
BMC Genomics


. 2022 Jul 14;23(1):510.
doi: 10.1186/s12864-022-08756-6.
Phylogenetic analysis and comparative genomics of SARS-CoV-2 from survivor and non-survivor COVID-19 patients in Cordoba, Argentina


Nadia B Olivero[SUP] 1 [/SUP], Ana S Gonzalez-Reiche[SUP] 2 [/SUP], Viviana E Re[SUP] 3 4 5 [/SUP], Gonzalo M Castro[SUP] 4 [/SUP], María B Pisano[SUP] 3 [/SUP], Paola Sicilia[SUP] 4 [/SUP], María G Barbas[SUP] 5 [/SUP], Zenab Khan[SUP] 2 [/SUP], Adriana van de Guchte[SUP] 2 [/SUP], Jayeeta Dutta[SUP] 2 [/SUP], Paulo R Cortes[SUP] 1 [/SUP], Mirelys Hernandez-Morfa[SUP] 1 [/SUP], Victoria E Zappia[SUP] 1 [/SUP], Lucia Ortiz[SUP] 6 [/SUP], Ginger Geiger[SUP] 6 [/SUP], Daniela Rajao[SUP] 6 [/SUP], Daniel R Perez[SUP] 6 [/SUP], Harm van Bakel[SUP] 2 7 8 [/SUP], Jose Echenique[SUP] 9 [/SUP]



Affiliations

Abstract

Background: The SARS-CoV-2 virus is responsible for the COVID-19 pandemic. To better understand the evolution of SARS-CoV-2 early in the pandemic in the Province of Cordoba, Argentina, we performed a comparative genomic analysis of SARS-CoV-2 strains detected in survivors and non-survivors of COVID-19. We also carried out an epidemiological study to find a possible association between the symptoms and comorbidities of these patients with their clinical outcomes.
Results: A representative sampling was performed in different cities in the Province of Cordoba. Ten and nine complete SARS-CoV-2 genomes were obtained by next-generation sequencing of nasopharyngeal specimens from non-survivors and survivors, respectively. Phylogenetic and phylodynamic analyses revealed multiple introductions of the most common lineages in South America, including B.1, B.1.1.1, B.1.499, and N.3. Fifty-six mutations were identified, with 14% of those in common between the non-survivor and survivor groups. Specific SARS-CoV-2 mutations for survivors constituted 25% whereas for non-survivors they were 41% of the repertoire, indicating partial selectivity. The non-survivors' variants showed higher diversity in 9 genes, with a majority in Nsp3, while the survivors' variants were detected in 5 genes, with a higher incidence in the Spike protein. At least one comorbidity was present in 60% of non-survivor patients and 33% of survivors. Age 75-85 years (p = 0.018) and hospitalization (p = 0.019) were associated with non-survivor patients. Related to the most common symptoms, the prevalence of fever was similar in both groups, while dyspnea was more frequent among non-survivors and cough among survivors.
Conclusions: This study describes the association of clinical characteristics with the clinical outcomes of survivors and non-survivors of COVID-19 patients, and the specific mutations found in the genome sequences of SARS-CoV-2 in each patient group. Future research on the functional characterization of novel mutations should be performed to understand the role of these variations in SARS-CoV-2 pathogenesis and COVID-19 disease outcomes. These results add new genomic data to better understand the evolution of the SARS-CoV-2 variants that spread in Argentina during the first wave of the COVID-19 pandemic.

Keywords: COVID-19; Comparative genomics; Genomes; Infectious diseases; Molecular epidemiology; SARS-CoV-2; Sequencing; Severe acute respiratory syndrome coronavirus 2.
 
Back
Top Bottom